Bibliography
- Houslay MD, Schafer P, Zhang KY. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 2005;15:1503-19
- Rose GM, Hopper A, De Vivo, Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 2005;11:3329-34
- Ghavami A, Hirst WD, Novak TJ. Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit? Drugs RD 2006;7:63-71
- Zhang KY, Ibrahim PN, Gillette S, Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets 2005;9:1283-305
- Spina D. PDE4 inhibitors: current status. Br J Pharmacol 2008;155:308-15
- Calverley PM, Sanchez-Toril F, McIvor A, Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61
- Rennard SI, Schachter N, Strek M, Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006;129:56-66
- Souness JE, Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997;9:227-36
- Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008;155:288-90
- Rabe KF, Bateman ED, O'Donnell D, Roflumilast–an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71
- Calverley PM, Sanchez-Toril F, McIvor A, Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176:154-61
- Nycomed confirms positive trend in third quarter 2008. (Press release 12.08.2008). Available from: http://www.nycomed.com/en/Menu/Media/News+releases/. [Last accessed 8 July 2009]
- Nycomed files European marketing authorisation application for Daxas® in COPD. (Press release 08.05.2009). Available from: http://www.nycomed.com/en/Menu/Media/News+releases/. [Last accessed 8 July 2009]
- Vakkalanka SKVS, Balasubramaniam LA, Gharat LA, The pharmacological and safety profile of a novel selective phosphodiesterase-4 (PDE4) inhibitor:GRC-3886. Eur Respir J 2004;24:1391
- Phase II-b trials for Oglemilast(GRC 3886) in Asthma initiated.(Press release: 10.10.2008). Available from: http://www.glenmarkpharma.com/media/pdf/releases/Release-PhaseII-b_trials_for_Oglemilast_GRC_3886.pdf. [Last accessed 8 July 2009]
- Odingo JO. Inhibitors of PDE4: a review of recent patent literature. Expert Opin Ther Patents 2005;15(7):773-87
- OX914–against COPD and asthma. Available from: http://www.orexo.com/ en/Portfolio/OX-914/. [Last accessed 13 July 2009]
- Shafer P. Maximizing efficacy of phosphodiesterase 4 inhibitors for COPD and asthma. SMI Conference on chronic obstructive pulmonary disorders, London; 2005
- Gottlieb AB, Strober B, Krueger JG, An open-label, single-arm pilot study in paients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 2008;24(5):1529-38
- Papp K, Zeldis J, Rohane P, A phase 2 study demonstrating the efficacy and safety of the oral therapy CC-10004 in subjects with moderate to severe psoriasis. J Am Acad Dermatol 2008;58:AB3
- Clinical trials.gov. A service of the US National Institutes of Health. Search of CC- 10004. Available from: http://www.clinicaltrials.gov/ct2/results?term=cc-10004. [Last accessed 13 July 2009]
- Efficacy, safety and tolerability of MEM 1414 on allergen-induced late asthmatic response in steroid-free subjects with mild allergic asthma. Available from: http://www.controlled-trials.com/ISRCTN48047493. [Last accessed 10 July 2009]
- PDE-4 Inhibitor [GRC 4039] - Rheumatoid Arthritis, Inflammation. Available from: http://www.glenmarkpharma.com/research/clinical_02.html. [Last accessed 13 July 2009]
- Kuss H, Egerland U, Hoefgen N, The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD. Eur Resp J 2003;22(Suppl 45):P742
- Kuss H, Hoppmann J, Egerland U, ELB353, a new selective PDE4-inhibitor with a high safety margin and anti-inflammatory effects in rat and ferret lungs [abstract]. 7th World Congr Inflamm (August 20-24, Melbourne); 2005
- Kronbach T. Discovery and development of subtype selective PD inhibitors in a 11-dimentional space. 3rd annual phosphodiesterases in drug discovery and development, Philadelphia; 2005
- ELB353, an oral PDE4 inhibitor for COPD in clinical development. Available from: http://www.biotie.com/WebRoot/1009506/StockNewsDetails.aspx?id=1013836&NewsItemID=1315196&NewsItemYear=2009. [Last accessed 8 July 2009]
- Altana Pharma AG. WO2005090345; 2005
- Altana Pharma AG. WO2005012252; 2005
- Altana Pharma AG. WO2005012253; 2005
- Altana Pharma AG. WO2005077906; 2005
- Altana Pharma AG. WO2005084104; 2005
- Altana Pharma AG. WO2005085225; 2005
- Altana Pharma AG. WO2005087744; 2005
- Altana Pharma AG. WO2005087745; 2005
- Altana Pharma AG. WO2005090311; 2005
- Altana Pharma AG. WO2006082185; 2006
- Altana Pharma AG. WO2006092417; 2006
- Altana Pharma AG. WO2006092422; 2006
- Altana Pharma AG. WO2006095009; 2006
- Altana Pharma AG. WO2005023253; 2005
- Altana Pharma AG. WO2005085203; 2005
- Altana Pharma AG. WO2006027344; 2006
- Altana Pharma AG. WO2006027345; 2006
- Altana Pharma AG. WO2005075437; 2005
- Altana Pharma AG. WO2005075456; 2005
- Altana Pharma AG. WO2008138939; 2008
- Altana Pharma AG. WO2005075457; 2005
- Altana Pharma AG. WO2005082361; 2005
- Altana Pharma AG. WO2006120176; 2006
- Altana Pharma AG. WO2008003701; 2008
- Altana Pharma AG. WO2006094933; 2006
- Altana Pharma AG. WO2006111495; 2006
- Altana Pharma AG. WO2005107749; 2005
- GlaxoSmithKline. WO2005030212; 2005
- GlaxoSmithKline. WO2007107499; 2007
- Lunniss CJ, Cooper AWJ, Eldred CD, Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration. Bioorg Med Chem Lett 2009;19:1380-5
- Woodrow MD, Ballantine SP, Barker MD, Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration. Bioorg Med Chem Lett 2009; published online 9 April 2009, doi: 10.1016/j.bmcl.2009.04.012
- GlaxoSmithKline. WO2005030725; 2005
- GlaxoSmithKline. WO2006053784; 2006
- GlaxoSmithKline. WO2006097340; 2006
- GlaxoSmithKline. WO2006089689; 2006
- GlaxoSmithKline. WO2007045861; 2007
- GlaxoSmithKline. WO2005058892; 2005
- GlaxoSmithKline. WO2005090348; 2005
- GlaxoSmithKline. WO2005090353; 2005
- GlaxoSmithKline. WO2005090354; 2005
- GlaxoSmithKline. WO2005090352; 2005
- GlaxoSmithKline. WO2007036733; 2007
- GlaxoSmithKline. WO2007036734; 2007
- GlaxoSmithKline. WO2008015416; 2008
- GlaxoSmithKline. WO2008015437; 2008
- GlaxoSmithKline. WO2008009735; 2008
- Hamblin JN, Angell TDR, Ballantine SP, Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorg Med Chem Lett 2008;18:4237-41
- Pfizer. WO2005009965; 2005
- Pfizer. WO2005009966; 2005
- Pfizer. US2005026952; 2005
- Pfizer. US2005020626; 2005
- Pfizer. US2005020587; 2005
- Pfizer. US2005020639; 2005
- Mathias J. Structure based design of PDE4 inhibitors as potential inhaled anti-inflammatories. SCI Meeting Respiratory Disease: Progress in Medicinal Chemistry, London; 2008
- Pfizer. US2005020611; 2005
- Pfizer. WO2006077497; 2006
- Pfizer. WO2005007138; 2005
- Boehringer Ingelheim. US2006116370; 2006
- Boehringer Ingelheim. US2006116371; 2006
- Boehringer Ingelheim. US2006116372; 2006
- Boehringer Ingelheim. US2006116373; 2006
- Boehringer Ingelheim. WO2007135026; 2007
- Boehringer Ingelheim. WO2007135027; 2007
- Boehringer Ingelheim. WO2007014838; 2007
- Boehringer Ingelheim. WO2006111549; 2006
- Boehringer Ingelheim. US2007259846; 2007
- Boehringer Ingelheim. EP1847543; 2007
- Boehringer Ingelheim. WO2009050236; 2009
- Boehringer Ingelheim. WO2009050242; 2009
- Boehringer Ingelheim. WO2009050248; 2009
- Boehringer Ingelheim. WO2009053268; 2009
- Boehringer Ingelheim. WO2009052138; 2009
- Boehringer Ingelheim. WO2006114371; 2006
- AstraZeneca. WO2007004958; 2007
- AstraZeneca. WO2007108750; 2007
- AstraZeneca. WO2008084223; 2008
- AstraZeneca. WO2008084240; 2008
- AstraZeneca. WO2008084236; 2008
- AstraZeneca. WO2007040435; 2007
- Ranbaxy. WO2005051931; 2005
- Ranbaxy. EP1840123; 2007
- Ranbaxy. WO2005021515; 2005
- Ranbaxy. WO2005026095; 2005
- Ranbaxy. WO2006085212; 2006
- Ranbaxy. WO2006117653; 2006
- Ranbaxy. US2008009535; 2008
- Ranbaxy. WO2008035315; 2008
- Ranbaxy. WO2008035316; 2008
- Ranbaxy. WO2006129158; 2006
- Ranbaxy. WO2007029077; 2007
- Ranbaxy. WO2007031838; 2007
- Ranbaxy. WO2007031977; 2007
- Ranbaxy. WO2007045980; 2007
- Ranbaxy. WO2008111009; 2008
- Ranbaxy. WO2008111010; 2008
- Ranbaxy. WO2007046022; 2007
- Ranbaxy. EP1958947; 2008
- Celgene. WO2005046592; 2005
- Celgene. US2005239867; 2005
- Celgene. US2006025457; 2006
- Celgene. US20080234359; 2008
- Celgene. WO2006025991; 2006
- Celgene. WO2005110085; 2005
- Celgene. US2009010886; 2009
- Chiesi Farmaceutici SPA. WO200800659; 2008
- Chiesi Farmaceutici SPA. WO2009018909; 2009
- Kyorin. WO2006095666; 2006
- Kyorin. WO2008029882; 2008
- Kyorin. WO2008156094; 2008
- Kyorin. WO2008156102; 2008
- Kyorin. JP2009040711; 2009
- Kyorin. WO2008029829; 2008
- Kyorin. WO2008129624; 2008
- Kyowa Hakko. JP2005015354; 2005
- Kyowa Hakko. JP2005060375; 2005
- Kyowa Hakko. JP2005060376; 2005
- Kyowa Hakko. WO2005087749; 2005
- Glenmark Pharmaceuticals SA. WO2004069831; 2004
- Glenmark Pharmaceuticals SA. WO2004111044; 2004
- Glenmark Pharmaceuticals SA. WO2006051390l; 2006
- Glenmark Pharmaceuticals SA. WO2006011024; 2006
- Glenmark Pharmaceuticals SA. WO2006064355; 2006
- Glenmark Pharmaceuticals SA. WO2006040650; 2006
- Curacyte Discovery GmbH. WO2006010567; 2006
- Curacyte Discovery GmbH. EP1619196; 2006
- Matrix Laboratories. WO2008032171; 2008
- Memory Pharmaceuticals Corporation. WO2005061458; 2005
- Memory Pharmaceuticals Corporation. WO2006135828; 2006
- Memory Pharmaceuticals Corporation. WO2006044528; 2006
- Memory Pharmaceuticals Corporation. WO2007123953; 2007
- Memory Pharmaceuticals Corporation. WO2006044955; 2006
- Otsuka Pharmaceutical Company Ltd. WO2005111007; 2005
- Otsuka Pharmaceutical Company Ltd. WO2007058338; 2007
- Otsuka Pharmaceutical Company Ltd. WO2007148806; 2007
- Leo Pharma A/S. WO2008104175; 2008
- Leo Pharma A/S. WO2008077404; 2008
- Leo Pharma A/S. WO2008125111; 2008
- Plexxikon Inc. WO2006026754; 2006
- Plexxikon Inc. US2006041006; 2006
- Schering Corp. WO2005028471; 2005
- Schering Corp. WO2005116009; 2005
- Schering Corp. WO2008021235; 2008
- Schering Corp. WO2008008327; 2008
- Schering Corp. WO2009009002; 2009
- Schering Corp. WO2009009003l; 2009
- Almirall SA. WO2005049581; 2005
- Almirall SA. WO2005123692; 2005
- Almirall SA. WO2005123693; 2005
- Almirall SA. WO2006058723; 2006
- Almirall SA. WO2006058724; 2006
- Almirall SA. WO2007017078; 2007
- Dietsch GN, Dipalma CR, Eyre RJ, Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity. Toxicol Pathol 2006;34(1):39-51
- Losco PE, Evans EW, Barat SA, The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in cynomolgus monkeys. Toxicol Pathol 2004;32(3):295-308
- Hanton G, Sobry C, Daguès N, Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog. Toxicol Lett 2008;179(1):15-22
- Article in “The Independent”. Available from: http://www.independent.co.uk/news/business/news/trials-on-celltechs-asthma-drug-halted-595688.html. [Last accessed 1 September 2009]
- Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008;155:288-90
- Clinical trials.gov. A service of the US National Institutes of Health. Search of GW842470X. Available from: http://clinicaltrials.gov/ct2/results?intr=%22GW842470X+cream%22. [Last accessed 21 July 2009]
- Duplantier AJ, Bachert EL, Cheng JB, SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J Med Chem 2007;50:344-9
- Danto S, Wei GC, Gill J, A randomized, double-blind, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with persistent asthma. Am J Respir Crit Care Med 2007;175:A485
- Danto S, Wei GC, Gill J, A randomized, double-blind, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD. Am J Respir Crit Care Med 2007;175:A131
- Trevethick M, Banner K, Ballard S, UK-500,001, a potent selective inhibitor of phosphodiesterase type 4 (PDE4) designed for inhaled delivery, inhibits TNFalpha, MIP1beta and LTA4 release from native human blood cells. Am J Respir Crit Care Med 2007;175:A116
- Trevethick M, Philip J, Chaffe P, In vivo profile of intratracheally delivered phosphodiesterase type 4 (PDE4) inhibitor UK-500,001- inhibits bronchoconstriction and inflammation. Am J Respir Crit Care Med 2007;175:A927
- Philipps P, Bennetts M, Banner K, The PDE4 inhibitor UK-500,001 does not significantly inhibit airway responses to allergen and histamine [abstract 2964]. Eur Res J 2007:491s
- Vestbo J, Tan L, Atkinson G, A controlled trial of 6-weeks’ treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Res J 2009;33:1039-44
- Knowles RG, Tralau-Stewart C, Dawson J, In vitro characterization of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for topical administration. Am J Respir Crit Care Med 2009;179:A4581
- Knowles RG, Ball DI, Gascoigne MH, In vivo characterization of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for topical administration. Am J Respir Crit Care Med 2009;179:A4582
- Singh D, Cass L, Pétavy F, The inhaled PDE4 inhibitor GSK256066 significantly inhibits airway responses following allergen challenge in asthmatics. Eur Res J 2008;32:2732
- Boswell-Smith V, Spina D, Oxford AW, The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J Pharmacol Exp Ther 2006;318:840-8
- Anacore pipeline overview: AN2728. Available from: http://www.anacor.com/an2728.php. [Last accessed 14 July 2009]
- Santen: Research and Development. Available from: http://www.santen.com/ir/reports/ar2008_07.pdf. [Last accessed 14 July 2009]
- Lehnart SE, Wehrens XH, Reiken S, Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005;123(1):25-35, Erratum in: Cell 2005;123:535-6
- Robichaud A, Stamatiou PB, Jin SL, Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest 2002;110:1045-52
- Xu RX, Hassel AM, Vanderwall D, Atomic Structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Science 2000;288:1822-5